CDBIO(688739)2023-10-26 16:00Financial Performance - Q3 2023 revenue was CNY 463,385,149.41, a decrease of 3.25% year-over-year[20]. - Net profit attributable to shareholders was CNY 129,906,033.10, down 37.57% compared to the same period last year[20]. - Net profit excluding non-recurring items was CNY 118,659,920.09, a decline of 38.73% year-over-year[20]. - The company's net profit attributable to shareholders was ¥463,517,560.88, a decrease of 21.3% compared to ¥589,155,273.08 in the same period last year[35]. - Basic earnings per share decreased to ¥1.11 from ¥1.41, reflecting a decline of 21.3% year-over-year[35]. - Net profit for the first three quarters of 2023 was ¥585,077,583.55, down 11.4% from ¥660,628,425.10 in 2022[55]. - The total comprehensive income for the period was ¥463,517,560.88, down from ¥589,155,273.08, indicating a significant decrease in overall profitability[35]. Assets and Liabilities - As of September 30, 2023, the total assets of the company amounted to ¥10,308,173,076.49, an increase from ¥10,068,803,034.83 as of December 31, 2022, representing a growth of approximately 2.38%[8]. - The total current assets as of September 30, 2023, were ¥7,438,629,853.24, slightly down from ¥7,650,699,559.96 at the end of 2022, indicating a decrease of approximately 2.76%[7]. - The company's long-term equity investments increased to ¥1,486,582,765.31 from ¥1,475,968,004.93, showing a growth of about 0.76%[8]. - The total liabilities increased to ¥298,706,931.99 from ¥201,931,108.37, marking an increase of approximately 47.8%[8]. - Total liabilities increased to ¥485,163,453.00 from ¥406,164,634.49, representing a growth of approximately 19.5% year-over-year[32]. - The total assets were CNY 10,068,803,034.83, reflecting a decrease of CNY 1,171,252.66 compared to the previous period[20]. - The total liabilities were CNY 254,430,833.92, showing a minor decrease of CNY 1,111,176.57[20]. - The company's total liabilities increased to ¥350,313,018.19, compared to ¥254,430,833.92 in the same period last year[54]. - The total equity of the company reached ¥9,957,860,058.30, up from ¥9,814,372,200.91 in the previous year[54]. Cash Flow - The net cash flow from investing activities was negative at -¥1,832,368,263.24, compared to a positive cash flow of ¥1,487,317,076.48 in the previous year[12]. - The cash flow from financing activities was negative at -¥442,976,729.03, compared to -¥417,398,843.48 in the previous year, indicating a decline in financing activities[12]. - Cash flow from operating activities for the year-to-date was CNY 442,469,509.15, an increase of 42.47%[20]. - Cash inflow from operating activities totaled ¥1,313,801,855.34, compared to ¥1,232,120,945.42 in the same period of 2022, reflecting a growth of 6.6%[56]. - The net cash flow from operating activities was 442,469,509.15, an increase from 310,572,683.78 in the previous period, representing a growth of approximately 42.3%[67]. - The net cash flow from investment activities was -1,785,197,972.29, compared to a positive 1,584,483,307.98 in the previous period, reflecting a significant decline[67]. Expenses - R&D expenses increased by 43.48% in the current period, driven by projects related to rabies vaccines and influenza vaccines[26]. - Research and development expenses totaled ¥97,112,374.73, accounting for 20.96% of operating revenue, an increase of 6.83 percentage points compared to the previous year[41]. - Sales expenses rose to ¥293,892,286.59, an increase of 9.8% from ¥267,516,373.96 in the previous year[48]. - Total operating costs increased to ¥764,513,158.97, up 6.4% from ¥718,731,679.43 in the previous year[48]. - Research and development expenses decreased to ¥139,290,606.86, a reduction of 14.3% compared to ¥162,544,758.79 in the same period last year[48]. Shareholder Information - The company distributed dividends totaling ¥416,299,100.00, which is consistent with the previous year's distribution of ¥416,240,677.40[12]. - The company reported a total of 29,409 common shareholders at the end of the reporting period[42]. - The company's equity attributable to shareholders rose slightly to ¥9,671,513,719.59 from ¥9,649,585,884.87, marking a 0.23% increase[41]. - Unallocated profits amounted to approximately 60,076.09[78].